Latest news with #BMOCapital
Business Insider
a day ago
- Business
- Business Insider
Replimune double downgraded to Underperform from Outperform at BMO Capital
BMO Capital double downgraded Replimune (REPL) to Underperform from Outperform with a price target of $2, down from $27. While the firm continues to think that RP1 represents a 'real drug,' the simple reality is that Replimune will likely need to re-run its clinical studies to get to approval and may not have enough cash on its books to get there, the analyst tells investors in a research note. The firm added that it believes more clarity on a path forward and significant restructuring are needed, while Replimune will likely underperform its peer group in the interim. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
4 days ago
- Business
- Yahoo
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
5 days ago
- Business
- Business Insider
BMO Capital Keeps Their Buy Rating on Capital Power (CPX)
BMO Capital analyst Benjamin Pham maintained a Buy rating on Capital Power yesterday and set a price target of C$64.00. The company's shares closed today at C$60.50. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Pham is a 5-star analyst with an average return of 8.7% and a 68.10% success rate. Pham covers the Utilities sector, focusing on stocks such as Boralex Inc Cl A, Capital Power, and Algonquin Power & Utilities. Currently, the analyst consensus on Capital Power is a Moderate Buy with an average price target of C$64.29. Based on Capital Power's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$988 million and a net profit of C$151 million. In comparison, last year the company earned a revenue of C$1.12 billion and had a net profit of C$205 million Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CPX in relation to earlier this year.
Business Insider
5 days ago
- Business
- Business Insider
BMO Capital Sticks to Its Hold Rating for Canadian Utilities A (CU)
BMO Capital analyst Benjamin Pham maintained a Hold rating on Canadian Utilities A yesterday and set a price target of C$40.00. The company's shares closed today at C$38.37. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Pham is a 5-star analyst with an average return of 8.7% and a 68.10% success rate. Pham covers the Utilities sector, focusing on stocks such as Boralex Inc Cl A, Capital Power, and Algonquin Power & Utilities. Canadian Utilities A has an analyst consensus of Hold, with a price target consensus of C$40.40. The company has a one-year high of C$38.85 and a one-year low of C$30.41. Currently, Canadian Utilities A has an average volume of 486.1K. Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CU in relation to earlier this year.
